Biocept Stock Analysis

BIOC
 Stock
  

USD 0.92  0.02  2.22%   

The current indifference towards the small price fluctuations of Biocept could raise concerns from investors as the firm is trading at a share price of 0.92 on 39,600 in volume. The company directors and management did not add any value to Biocept investors in September. However, most investors can still diversify their portfolios with Biocept to hedge their inherited risk against high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.81. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Biocept partners.
Continue to Trending Equities.
  
The Biocept stock analysis report makes it easy to digest most publicly released information about Biocept and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Biocept Stock analysis module also helps to analyze the Biocept price relationship with some important fundamental indicators such as market cap and management efficiency.

Biocept Stock Analysis Notes

The company has price-to-book (P/B) ratio of 0.45. Some equities with similar Price to Book (P/B) outperform the market in the long run. Biocept recorded a loss per share of 1.5. The entity had not issued any dividends in recent years. The firm had 1-10 split on the 8th of September 2020. Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California. Biocept operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 177 people. For more info on Biocept please contact Michael Nall at 858 320 8200 or go to https://biocept.com.

Biocept Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Biocept's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Biocept or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Biocept has some characteristics of a very speculative penny stock
Biocept has very high historical volatility over the last 90 days
Biocept has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 63.44 M. Net Loss for the year was (8.19 M) with profit before overhead, payroll, taxes, and interest of 23.48 M.
Latest headline from finance.yahoo.com: United States Liquid Biopsy Market Analysis Report 2022 Focus on Multi-gene Parallel Analysis Using NGS Single-gene Analysis Using PCR Microarrays - Analysis Forecasts 2017-2027 - Yahoo Finance

Biocept Upcoming and Recent Events

Earnings reports are used by Biocept to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Biocept previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report4th of April 2022
Next Financial Report11th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End4th of April 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Biocept SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Biocept prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Biocept investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Biocept specific information freely available to individual and institutional investors to make a timely investment decision.
22nd of August 2022
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
View
16th of August 2022
Other Events
View
14th of July 2022
Financial Statements and Exhibits. Regulation FD Disclosure
View
13th of July 2022
Submission of Matters to a Vote of Security Holders
View
27th of June 2022
Changes in Registrant's Certifying Accountant
View
13th of June 2022
Other Events
View
24th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
16th of May 2022
Other Events
View

Biocept Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Biocept is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Biocept backward and forwards among themselves. Biocept's institutional investor refers to the entity that pools money to purchase Biocept's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Vanguard Group IncCommon Shares655.7 K616 K
Globeflex Capital L PCommon Shares233.6 K220 K
Renaissance Technologies LlcCommon Shares175.5 K165 K
Blackrock IncCommon Shares157.9 K148 K
Geode Capital Management LlcCommon Shares137.9 K129 K
Citadel Advisors LlcCall Options114.5 K108 K
Bridgeway Capital Management LlcCommon Shares109.4 K103 K
Millennium Management LlcCommon Shares103.1 K97 K
Note, although Biocept's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Biocept Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 13.47 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Biocept's market, we take the total number of its shares issued and multiply it by Biocept's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Biocept Profitablity

Biocept's profitability indicators refer to fundamental financial ratios that showcase Biocept's ability to generate income relative to its revenue or operating costs. If, let's say, Biocept is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Biocept's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Biocept's profitability requires more research than a typical breakdown of Biocept's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (12.91) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (12.26) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.12.

Management Efficiency

The entity has return on total asset (ROA) of (8.66) % which means that it has lost $8.66 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (25.68) %, meaning that it created substantial loss on money invested by shareholders. Biocept management efficiency ratios could be used to measure how well biocept manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 2nd of October, Biocept shows the Downside Deviation of 4.04, mean deviation of 2.73, and Risk Adjusted Performance of 0.0087. Biocept technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down and interpolate data for nineteen technical drivers for Biocept, which can be compared to its rivals. Please confirm Biocept information ratio and the relationship between the maximum drawdown and skewness to decide if Biocept is priced correctly, providing market reflects its regular price of 0.92 per share. Given that Biocept is a hitting penny stock territory we recommend to closely look at its total risk alpha.

Biocept Price Movement Analysis

The output start index for this execution was one with a total number of output elements of sixty. The Parabolic SAR indicator is used to determine the direction of Biocept's momentum and the point in time when Biocept has higher than normal probability directional change.
.

Biocept Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biocept insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biocept's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Biocept insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Biocept Predictive Daily Indicators

Biocept intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Biocept stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Biocept Forecast Models

Biocept time-series forecasting models is one of many Biocept's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Biocept's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Biocept Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Biocept prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Biocept shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Biocept. By using and applying Biocept Stock analysis, traders can create a robust methodology for identifying Biocept entry and exit points for their positions.
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California. Biocept operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 177 people.

Current Biocept Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Biocept analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Biocept analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
13.0Strong Buy2Odds
Biocept current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Biocept analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Biocept stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Biocept, talking to its executives and customers, or listening to Biocept conference calls.
Biocept Analyst Advice Details

Biocept Stock Analysis Indicators

Biocept stock analysis indicators help investors evaluate how Biocept stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Biocept shares will generate the highest return on investment. By understating and applying Biocept stock analysis, traders can identify Biocept position entry and exit signals to maximize returns.
Quick Ratio3.12
Fifty Two Week Low0.7170
Revenue Growth12.30%
Shares Short Prior Month218.99k
Average Daily Volume Last 10 Day46.56k
Average Daily Volume In Three Month83.05k
Shares Percent Shares Out0.73%
Gross Margins38.38%
Short Percent Of Float0.73%
Forward Price Earnings-0.56
Float Shares16.92M
Fifty Two Week High4.4000
Enterprise Value To Ebitda-0.22
Fifty Day Average0.9958
Two Hundred Day Average1.9016
Enterprise Value To Revenue0.02
Continue to Trending Equities. You can also try Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

Complementary Tools for analysis

When running Biocept price analysis, check to measure Biocept's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biocept is operating at the current time. Most of Biocept's value examination focuses on studying past and present price action to predict the probability of Biocept's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Biocept's price. Additionally, you may evaluate how the addition of Biocept to your portfolios can decrease your overall portfolio volatility.
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Is Biocept's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biocept. If investors know Biocept will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biocept listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Biocept is measured differently than its book value, which is the value of Biocept that is recorded on the company's balance sheet. Investors also form their own opinion of Biocept's value that differs from its market value or its book value, called intrinsic value, which is Biocept's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biocept's market value can be influenced by many factors that don't directly affect Biocept's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biocept's value and its price as these two are different measures arrived at by different means. Investors typically determine Biocept value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biocept's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.